BEAM THERAPEUTICS INC. - COMMON STOCK

Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT

25 Oct 2023 03:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline

19 Oct 2023 05:45:00 By Nasdaq GlobeNewswire

Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation

07 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL

05 Sep 2023 03:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in Upcoming September Investor Conferences

31 Aug 2023 03:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results

08 Aug 2023 03:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in Upcoming May Investor Conferences

17 May 2023 03:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in RBC Capital Markets 2023 Global Healthcare Conference

11 May 2023 03:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results

10 May 2023 03:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day

27 Mar 2023 04:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer

21 Mar 2023 03:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference

15 Mar 2023 03:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the 43rd Annual Cowen Healthcare Conference

01 Mar 2023 03:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones

28 Feb 2023 03:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference

07 Feb 2023 03:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones

09 Jan 2023 03:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 03:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Presents First In Vivo Proof of Concept Preclinical Data on Multiplex Base Edited ESCAPE Platform for Non-Genotoxic Conditioning Regimen for Patients with Sickle Cell Disease Ahead of Autologous Transplant

10 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022

02 Dec 2022 11:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201

02 Dec 2022 03:30:00 By Nasdaq GlobeNewswire